Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

Bristol Myers yields 4.4% with a 72% payout ratio and a 17-year consecutive dividend raise streak, but faces looming patent cliffs on key drugs Eliquis and Opdivo. Revenue was flat at $48.2B last year and management is guiding $46.0B–$47.5B this year, raising the risk of lower cash flow, potential acquisitions to shore up revenue, and a possible dividend cut. The author recommends avoiding BMY as a buy-and-forget income holding and instead suggests dividend-paying index funds.

Analysis

BMY’s near-term story is less about a single patent expiry and more about a multi-year margin re-pricing that can compound through three channels: price erosion on incumbents, accelerated reinvestment (or pricey M&A) to refill the pipeline, and a likely step-up in generic/biosimilar competition that reduces bargaining power with payors. Model a 10–20% erosion to core branded revenue over 24 months and BMY’s free cash flow profile flips from “dividend-funded optionality” to “defensive capital allocation,” forcing choices between dividend defense, debt issuance, or asset sales.

Second-order winners include contract manufacturers, biosimilar entrants, and index/ETF providers who will capture flows if retail de-risks from single-stock dividend exposure into diversified yield products. Banks and boutique M&A advisors also win if BMY pursues bolt-on deals to offset patent losses; conversely, mid-cap biotech and generic producers face pricing pressure as incumbents pursue price concessions to slow volume loss.

Risk calendar: near-term catalysts are quarterly guidance revisions and any litigation rulings/settlements (days–months), mid-term is launch timing/market penetration of biosimilars (6–24 months), and a tail (positive) outcome would be surprise label expansions or a defensive, accretive acquisition funded with non-dilutive cash. Monitor gross margin trajectory, incremental R&D vs. BD&A spend, and debt metrics — a meaningful step-up in leverage or a change in buyback cadence would materially shift the dividend risk calculus.

Key Decisions for Investors

• Short BMY via a 9–12 month put spread (sell a nearer-term 0.30–0.35 delta put and buy a deeper 0.55–0.60 delta put to fund cost) — target payoff if shares gap down 15–30% on generic/biosimilar penetration. Rationale: asymmetric downside protection with capped/maximal loss equal to the width of the spread; expected return 2–4x option premium if catalysts materialize within 6–12 months. Monitor: legal rulings and quarterly guidance weeks.
• Relative-value pair: short BMY equity vs long a diversified dividend ETF (eg. SCHD/VIG) sized 1:1 over 6–18 months — this isolates company-specific dividend risk from sector/dividend beta. Risk/reward: reduces market exposure; if BMY cuts or underperforms, expect pair to gain mid- to high-single-digit percent; downside if healthcare defensives rerate higher across the board.
• Rotate a portion of dividend-seeking capital into secular growth via NVDA LEAPs (buy Jan-2027 calls) financed by small size short BMY 6–12 month puts (cash-secured) — trade objective: replace concentrated yield exposure with asymmetric growth optionality while maintaining modest income from short puts. Risk: NVDA remains high-volatility; short puts may be assigned if BMY gaps lower, so size to cash/collateral.
• Event hedge: if BMY announces a large, debt-funded acquisition to shore up its pipeline, buy short-dated calls (buy 1–3 month call spreads) to capture a positive rerating while keeping premium risk limited. Reward: quick capture of M&A-driven pop; risk: tie-up terms may dilute equity and the long-term cash strain remains.